Disease · MONDO_0003406

sleep-wake disorder

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. sleep-wake disorder. Diseases, record MONDO_0003406. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0003406

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: sleep-wake disorder; Open Targets
Open Targets ID: MONDO_0003406; Open Targets
Other names: disorder of sleep-wake cycle; Open Targets
Disease Ontology: DOID:535; Disease Ontology
MeSH: D012893; MeSH
Highest stage of its drugs: Approval, for 2 of its 10 drugs, from DailyMed and TTD; Open Targets

Drugs10

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
TASIMELTEON	CHEMBL2103822	Small molecule	Approval	DailyMed	4	3	3	Drugs and targets
ACEPROMETAZINE	CHEMBL2104054	Small molecule	Approval	TTD	1	0	0	Drugs and targets
EPLIVANSERIN FUMARATE	CHEMBL2103845	Small molecule	Phase 3	TTD	1	0	0	Drugs and targets
VOLINANSERIN	CHEMBL74355	Small molecule	Phase 3	TTD	1	0	0	Drugs and targets
ADIPIPLON	CHEMBL2103791	Small molecule	Phase 2	TTD	1	0	0	Drugs and targets
DIMDAZENIL	CHEMBL5095096	Small molecule	Phase 2	TTD	1	0	0	Drugs and targets
NELOTANSERIN	CHEMBL598172	Small molecule	Phase 2	TTD	1	0	0	Drugs and targets
PRUVANSERIN	CHEMBL1215661	Small molecule	Phase 2	TTD	1	0	0	Drugs and targets
ALMOREXANT	CHEMBL455136	Small molecule	Unknown	TTD	1	0	0	Drugs and targets
LUZINDOLE	CHEMBL286615	Small molecule	Unknown	TTD	1	0	0	Drugs and targets

Targets21

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
HTR2A	5-hydroxytryptamine receptor 2A	3	Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2a (5-HT2a) receptor inverse agonist	Phase 3	https://conductscience.org/library/genes/3356	Drugs and targets
GABRA1	GABA-A receptor; anion channel	1	GABA-A receptor; anion channel partial agonist	Phase 2	https://conductscience.org/library/genes/2554	Drugs and targets
GABRA2	GABA-A receptor; anion channel	1	GABA-A receptor; anion channel partial agonist	Phase 2	https://conductscience.org/library/genes/2555	Drugs and targets
GABRA3	GABA-A receptor; anion channel	1	GABA-A receptor; anion channel partial agonist	Phase 2	https://conductscience.org/library/genes/2556	Drugs and targets
GABRA4	GABA-A receptor; anion channel	1	GABA-A receptor; anion channel partial agonist	Phase 2	https://conductscience.org/library/genes/2557	Drugs and targets
GABRA5	GABA-A receptor; anion channel	1	GABA-A receptor; anion channel partial agonist	Phase 2	https://conductscience.org/library/genes/2558	Drugs and targets
GABRA6	GABA-A receptor; anion channel	1	GABA-A receptor; anion channel partial agonist	Phase 2	https://conductscience.org/library/genes/2559	Drugs and targets
GABRB1	GABA-A receptor; anion channel	1	GABA-A receptor; anion channel partial agonist	Phase 2	https://conductscience.org/library/genes/2560	Drugs and targets
GABRB2	GABA-A receptor; anion channel	1	GABA-A receptor; anion channel partial agonist	Phase 2	https://conductscience.org/library/genes/2561	Drugs and targets
GABRB3	GABA-A receptor; anion channel	1	GABA-A receptor; anion channel partial agonist	Phase 2	https://conductscience.org/library/genes/2562	Drugs and targets

1 to 10 of 21

See all 21 targets

Trials3

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01163032	Efficacy and Safety of Tasimelteon Compared With Placebo in Totally Blind Subjects With Non-24-Hour Sleep-Wake Disorder	Phase 3	136	2014-10-16	Non-24-Hour Sleep-Wake Disorder	TASIMELTEON	Open Targets' reading, confirmed by NLM's indexing of its papers	ClinicalTrials.gov
NCT01430754	Withdrawal Study to Demonstrate the Maintenance Effect in the Treatment of Non-24-Hour Sleep-Wake Disorder	Phase 3	20	2014-10-10	Non-24-Hour Sleep-Wake Disorder	TASIMELTEON	Open Targets' reading, confirmed by NLM's indexing of its papers	ClinicalTrials.gov
NCT01429116	Tasimelteon for the Treatment of Non-24-hour Sleep-Wake Disorder (N24HSWD) in Blind Individuals With no Light Perception	Phase 3	200		Non-24-Hour Sleep-Wake Disorder	TASIMELTEON	Open Targets' reading of its record	ClinicalTrials.gov

Comparisons in its trials2

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Tasimelteon vs Placebo: Maintenance of Entrainment (aMT6s) in Subjects With N24HSWD.	9 of 10	2 of 10	20	NCT01430754	Trial comparisons
Tasimelteon vs Placebo: Maintenance of Entrainment (Cortisol) in Subjects With N24HSWD	8 of 10	2 of 10	20	NCT01430754	Trial comparisons

Papers from its trials1

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it
26466871	DERIVED	2

Source PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0003406

GET https://conductscience.org/api/diseases/v1/MONDO_0003406/targets?page=2

API reference For AI assistants